Orgenesis, Inc. (NASDAQ:ORGS) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET

Company Participants

David Waldman – Investor Relations

Vered Caplan – Chief Executive Officer

Neil Reithinger – Chief Financial Officer

Conference Call Participants

Bruce Jackson – The Benchmark Company

Operator

Good day, ladies and gentlemen, and welcome to the Orgenesis Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, David Waldman from Investor Relations. Sir, the floor is yours.

David Waldman

Thank you, and good morning, everyone, and welcome to Orgenesis second quarter 2022 business update conference call. On the call with us this morning are Vered Caplan, Chief Executive Officer; and Neil Reithinger, Chief Financial Officer. If you have any questions after the call, would like any additional information about the company, please contact Crescendo Communications at 212-671-1020.

This conference call contains forward-looking statements, which are made pursuant to the Safe Harbor provisions of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities and Exchange Act of 1934 as amended. These forward-looking statements involve substantial uncertainties and risks that are based upon current expectations estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this conference call. We caution listeners that forward-looking statements are predictions based on our current expectations about future events.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Their actual performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the risk factors and uncertainties discussed under the heading Risk Factors in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

I’d now like to turn the call over to Orgenesis CEO, Ms. Vered Caplan. Please go ahead, Vered.

Vered Caplan

Thank you, David, and thanks to everyone for joining us on our call today. I’m always glad to have a chance to speak directly to shareholders. And as many of you know, we really excited to be responsive and available [Technical Difficulty]. We also appreciate that the support we have received pharmacy license. The last several months have been one of much turmoil, political issues, economic instability and many are still suffering from the latest [indiscernible], while no new biological tax appear around the corner. These issues have not had a direct influence are now is physical. But they have affected investors and shareholders without the biotech industry. And many companies have not survived these, that have been chosen shareholders that have had to liquidate their assets quickly and the general mood of the biotech investment.